Clinical Trial Update: Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

The document reports that a Phase 1 study evaluating allogeneic CD6-CAR T regulatory cells for chronic graft-versus-host disease after allogeneic hematopoietic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Steroid-refractory Graft-versus-host Disease

Drugs mentioned

• Allogeneic CD6-CAR T regulatory cells (CD6-CAR Tregs)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Status: SUSPENDED